The promoter gene polymorphism of CYP19A1 has been linked with the risk of hepatocellular carcinoma [21, 22]; in addition, it can promote the metastatic homing and proliferation of stem-like prostate cancer cells in the bone marrow [23]. This evidence concerns the gene CYP19A1 and prostate carcinoma.